Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Neurologic Immune Reconstitution Inflammatory Syndrome in HIV/AIDS: Outcome and Epidemiology
Neurol 72:835-841, McCombe,J.A.,et al, 2009
Thrombolytic Therapy for Patients Who Wake-Up With Stroke
Stroke 40:827-832, Barreto,A.D.,et al, 2009
A Multicenter, Prospective Pilot Study of Gamma Knife Radiosurgery for Mesial Temporal Lobe Epilepsy: Seizure Response, Adverse Events, and Verbal Memory
Ann Neurol 65:167-175, Barbaro,N.M.,et al, 2009
Posterior Reversible Encephalopathy Syndrome After Intravenous Caffeine for Post-Lumbar Puncture Headaches
AJNR 30:586-587, Ortiz,G.A.,et al, 2009
Hepatitis B Vaccine and the Risk of CNS Inflammatory Demyelination in Childhood
Neurol 72:873-880,870, Mikaeloff,Y.,et al, 2009
Community-Acquired Bacterial Meningitis in Elderly Patients: Experience Over 30 Years
Medicine 88:115-119, Cabellos,C.,et al, 2009
Sustained-Release Oral Fampridine in Multiple Sclerosis: A Randomised, Double-Blind, Controlled Trial
Lancet 373:732-738, Goodman,A.D.,et al, 2009
Unexplained Seizures in an Infant
Lancet 373:94, Astuto,M.,et al, 2009
Carbon Monoxide Poisoning
NEJM 360:1217-1225, Weaver,L.K., 2009
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
PML-IRIS in Patients with HIV Infection: Clinical Manifestations and Treatment with Steroids
Neurol 72:1458-1464,1454, Tan,K.,et al, 2009
Identifying Patients at High Risk for Poor Outcomes After Intra-Arterial Therapy for Acute Ischemic Stroke
Stroke 40:1780-1785, Hallevi,H.,et al, 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Overweight After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease: Long Term Follow-Up
JNNP 80:484-488, Bannier,S.,et al, 2009
High Doses of Deferiprone May Be Associated with Cerebellar Syndrome
BMJ 338:653, Beau-Salinas,F.,et al, 2009
Fast-In, Fast-Out
Lancet 373:1398, Hefele,B.,et al, 2009
Prior Antiplatelet Use Dose Not Affect Hemorrhage Growth or Outcome After ICH
Neurol 72:1397-1402,1376, Sansing,L.H.,et al, 2009
Cognitive Function at 3 Years of Age After Fetal Exposure to Antiepileptic Drugs
NEJM 360:1597-1605,1667, Meador,K.J.,et al, 2009
Deep Brain Stimulation for Primary Generalized Dystonia: Long-Term Outcomes
Arch Neurol 66:465-470, Isaias,I.U.,et al, 2009
Community-Acquired Bacterial Meningitis in Elderly Patients: Experience over 30 Years
Medicine 88:115-119, Cabellos,C.,et al, 2009
Recurrent Pericarditis Due to Natalizumab Treatment
Neurol 72:1616-1617, Cohen,M.,et al, 2009
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
A Systematic Review of Antiepilpetic Drug Initiation and Withdrawal
The Neurologist 15:122-131, Shih,J.J &Ochoa,J.G., 2009
Antivenom for Critically Ill Children with Neurotoxicity from Scorpion Stings
NEJM 360:2090-2098, Boyer,L.V.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Fomepizole for Ethylene Glycol and Methanol Poisoning
NEJM 360:2216-2223, Brent,J., 2009
Intracerebral Haemorrhage
Lancet 373:1632-1644, Qureshi,A.I.,et al, 2009
Hippocampal Lesion Patterns in Acute Posterior Cerebral Artery Stroke: Clinical and MRI Findings
Stroke 40:2042-2045, Szabo,K.,et al, 2009
Thrombolysis in Young Adults with Ischemic Stroke
Stroke 40:2085-2091, Putaala,J.,et al, 2009
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009
Neurological Consequences of Atrioesophageal Fistula After Radiofrequency Ablation in Atrial Fibrillation
Arch Neurol 66:884-887, St�llberger,C.,et al, 2009
Long-Term Effects of Pallidal Deep Brain Stimulation in Tradive Dystonia
Neurol 73:53-58, Gruber,D.,et al, 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis
Stroke 40:2438-2441, Lansberg,M.G.,et al, 2009
A 70-Year-Old Woman with Shingles: Review of Herpes Zoster
JAMA 302:73-80,108, Whitley,R.J., 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Acute Disseminated Encephalomyelitis Following Vacicnation Against Human Papilloma Virus
Neurol 72:2132-2133, Wildemann,B.,et al, 2009
The Risks and Costs of Multiple-Generic Substitution of Topiramate
Neurol 72:2122-2129, Duh,M.S.,et al, 2009
Use of Antithrombotic Drugs and the Presence of Cerebral Microbleeds: The Rotterdam Scan Study
Arch Neurol 66:714-720,691, Vernooij,M.W.,et al, 2009
Effectiveness of Thigh-Length Graduated Compression Stockings to Reduce the Risk of Deep Vein Thrombosis After Stroke (CLOTS Trial 1): A Multicentre, Randomised Controlled Trial
Lancet 373:1958-1965,1923, The CLOTS Trial Collaboration, 2009
Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomised Non-Inferiority Trial
Lancet 374:534-542,504, Holmes,D.R.,et al, 2009
Point-of-Care International Normalized Ratio Testing Accelerates Thrombolysis in Patients With Acute Ischemic Stroke Using Oral Anticoagulants
Stroke 40:3547-3551, Rizos,T.,et al, 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009
The Clinical Course of Advanced Dementia
NEJM 361:1529-1538, 1595, Mitchell,S.,et al, 2009
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009